Cannabix Technologies Correlates THC in Breath and Blood using Proprietary Sample Collection and Analysis Hardware in Southern US Study
August 25th, 2022
News, Top News
For immediate release. Vancouver, British Columbia, August 25, 2022: Cannabix Technologies Inc.(CSE: BLO, OTC PINK CURRENT: BLOZF) (the “Company”) developer of marijuana breathalyzer devices for law enforcement and the workplace reports it continues to successfully test a supplemental version of its FAIMS technology for detection of ∆9-tetrahydrocannabinol (“THC”) and related analytes in human breath in new comprehensive multi-analysis study of subjects under the influence of marijuana in the southern United States (see July 12, 2022 news release). In the Southern US study, Cannabix is working alongside toxicologists and law enforcement officers who are testing subjects under the influence of marijuana. The Company’s technology (proprietary breath capture and marijuana detection equipment, described below) is being used side by side with several conventional drug screening methods (blood, oral fluid etc.). Further details of the study will be available in due course when disclosure approvals are granted to the Company.
In June and July, Cannabix participated in two testing day events held in two different US cities. Early study data is demonstrating very consistent correlation of levels of THC between breath samples collected and analyzed with Cannabix hardware and the current standard of whole blood. The Company’s updated handheld Breath Collection Unit (“BCU”, Fig. 1) and newly developed laboratory “MS Breath Sampler” (Fig. 2) were used together to provide a new ground-breaking method for drug detection that complements gold-standard mass spectrometry (MS), and significantly simplifies laboratory analysis methods, reduces sample turnaround time thus minimizing operating costs, while maintaining sensitive, precise results.
The Company has developed a unique breath capture system, capable of collecting low volatility analytes, such as THC, from approximately 5 breaths, which is the first time that such a capability for low volatility analytes has been developed. In addition, the Cannabix device captures analytes efficiently such that the sample preparation steps needed in traditional methods are completely eliminated. The system has detected and confirmed THC in breath out to 4 hours after smoking with breath samples being stored and analyzed up to two days after sample collection.
THC in Breath & Blood Data
Study results show that breath levels of THC over time are consistent between subjects and data is demonstrating consistent correlation of levels of THC between breath and whole blood in early time points after smoking.
The experimental studies reported here include 10 subjects (6 men, 4 women). Similar to Cannabix’s earlier experiments in Ontario (see press release from May 9th, 2022) breath samples were collected at baseline (a timepoint just before smoking cannabis) as well as two time points after smoking cannabis, out to 1 hour and 45 minutes. Blood samples were collected at baseline (n=4) and at one timepoint after smoking (between T7 and T30 min, n=10).
Breath samples were collected and analyzed using the same hardware and methods as in the previous experimental study in Ontario. Collection was done with the Cannabix BCU, and samples were analyzed using the Cannabix Mass Spectrometer (MS) Breath Sampler coupled to a Thermo TSQ Quantum Ultra MS running in tandem mode. THC and fragment ions were analyzed using Thermo Xcalibur software, and areas under the chromatogram curves (AUC) were determined using the software’s detection feature. Whole blood samples were collected using standardized collection kits by licensed phlebotomists recruited from a local hospital, and were analyzed at a local lab using LC/MS/MS, according to conventional standard operating procedures.
The resulting breath data from this study (see Fig. 3 below) follow the same trend that was seen with experimental data from Ontario study (Fig. 4). Breath and whole blood levels of THC were consistent and correlate well within the relatively short time window. Observed breath results further support literature (1) on trends in THC metabolism, similarly to the earlier results. In this study, the storage time between collection and analysis of the breath samples was up to 52 hours (compared to 40 hours in Ontario study).
This study further demonstrates that the Cannabix breath sampling and analysis tools function effectively in the field and provide quick and nonintrusive breath sample collection and ease of analysis with no sample preparation needed. In comparison, legacy breath and saliva testing procedures require several sample extraction and preparation steps prior to analysis, and analysis itself can take from 1 – 3 hours per sample. This is expensive and not amenable to high throughput operations. Also, legacy breath and saliva testing procedures have inefficient collection methods and recoveries are still often poor.
Blood is currently the standard of measurement for drug determination by law enforcement and toxicologists, and is used as objective evidence of possible impairment in courts of law. Cannabix’s simple and reliable breath collection and analysis method (thus far used in several small preliminary tests) shows very good correlation to blood, which is the standard method to detect and confirm acute cannabis use in the field.
The BCU is also being used in concert with the Cannabix FAIMS Detection Unit (FDU), which is being developed as a fully portable system capable of both breath collection and analyses in the field.
“Cannabix is seeking to work with provincial, state and federal agencies, toxicologists, crime labs and private industry to expand on these ground breaking methods of THC in breath collection and analysis”, stated CEO, Rav Mlait.
About Cannabix Technologies Inc.
Cannabix Technologies Inc. is a developer of marijuana breathalyzer technologies for law enforcement and the workplace. Cannabix is working to develop drug-screening devices that will detect THC- the psychoactive component of marijuana that causes impairment using breath samples. Breath testing for THC would allow employers and law enforcement to identify recent marijuana use that better aligns with impairment.
We seek Safe Harbor.
On behalf of the Board of Directors
Cannabix Technologies Inc.
For further information, contact us by visiting https://
Cautionary Statement Regarding Forward-Looking Statements
This press release contains forward-looking information that involves various risks and uncertainties regarding future events. Such forward-looking information can include without limitation statements based on current expectations involving a number of risks and uncertainties and are not guarantees of future performance of the Company, such as final development of a commercial or prototype product(s), successful trial or pilot of company technologies, no assurance that commercial sales of any kind actually materialize; no assurance the Company will have sufficient funds to complete product development. There are numerous risks and uncertainties that could cause actual results and the Company’s plans and objectives to differ materially from those expressed in the forward-looking information, including: (i) adverse market conditions; (ii) risks regarding protection of proprietary technology; (iii) the ability of the Company to complete financings; (iv) the ability of the Company to develop and market its future product; and (v) risks regarding government regulation, managing and maintaining growth, the effect of adverse publicity, litigation, competition and other factors which may be identified from time to time in the Company’s public announcements and filings. There is no assurance that its development of marijuana breathalyzer technology will provide any benefit to the Company, and no assurance that any proposed new products will be built, will be successful in beta testing or clinical trials. There is no assurance that existing “patent pending” technologies licensed by the Company will receive patent status by regulatory authorities. The Company is not currently selling commercial breathalyzers. Actual results and future events could differ materially from those anticipated in such information. These and all subsequent written and oral forward-looking information are based on estimates and opinions of management on the dates they are made and are expressly qualified in their entirety by this notice. Except as required by law, the Company does not intend to update these forward-looking statements.
Neither CSE nor its Regulation Services Provider accepts responsibility for the adequacy or accuracy of this release.
For additional information on Cannabix Technologies Inc. please visit our website at https://cannabixtechnologies.
This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.
Follow Us on Social Media
About CFN Media Group
CFN Enterprises Inc. (OTCQB: CNFN) owns and operates CFN Media Group, the premier agency and financial media network reaching executives, entrepreneurs and consumers worldwide. Through its proprietary content creation, video library, and distribution via www.CannabisFN.com, CFN has built an extensive database of cannabis interest, assisting many of the world’s largest cannabis firms and CBD brands to build awareness and thrive. For more information, please visit www.cfnenterprisesinc.com.
Disclaimer: Matters discussed on this website contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time-to-time have a position in the securities mentioned herein and will increase or decrease such positions without notice. The Information contains forward-looking statements, i.e. statements or discussions that constitute predictions, expectations, beliefs, plans, estimates, or projections as indicated by such words as "expects", "will", "anticipates", and "estimates"; therefore, you should proceed with extreme caution in relying upon such statements and conduct a full investigation of the Information and the Profiled Issuer as well as any such forward-looking statements. Any forward looking statements we make in the Information are limited to the time period in which they are made, and we do not undertake to update forward looking statements that may change at any time; The Information is presented only as a brief "snapshot" of the Profiled Issuer and should only be used, at most, and if at all, as a starting point for you to conduct a thorough investigation of the Profiled Issuer and its securities and to consult your financial, legal or other adviser(s) and avail yourself of the filings and information that may be accessed at www.sec.gov, www.pinksheets.com, www.otcmarkets.com or other electronic sources, including: (a) reviewing SEC periodic reports (Forms 10-Q and 10-K), reports of material events (Form 8-K), insider reports (Forms 3, 4, 5 and Schedule 13D); (b) reviewing Information and Disclosure Statements and unaudited financial reports filed with the Pink Sheets or www.otcmarkets.com; (c) obtaining and reviewing publicly available information contained in commonlyknown search engines such as Google; and (d) consulting investment guides at www.sec.gov and www.finra.com. You should always be cognizant that the Profiled Issuers may not be current in their reporting obligations with the SEC and OTCMarkets and/or have negative signs at www.otcmarkets.com (See section below titled "Risks Related to the Profiled Issuers, which provides additional information pertaining thereto). For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity-based compensation in the companies it writes about, or a combination of the two. For full disclosure, please visit: https://www.cannabisfn.com/legal-disclaimer/. A short time after we acquire the securities of the foregoing company, we may publish the (favorable) information about the issuer referenced above advising others, including you, to purchase; and while doing so, we may sell the securities we acquired. In addition, a third-party shareholder compensating us may sell his or her shares of the issuer while we are publishing favorable information about the issuer. Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time to time have a position in the securities mentioned herein and will increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity- based compensation in the companies it writes about, or a combination of the two. For full disclosure please visit: https://www.cannabisfn.com/legal-disclaimer/.